www.fdanews.com/articles/82276-impax-signs-exclusive-supply-and-distribution-agreement-with-dava-pharmaceuticals
IMPAX SIGNS EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENT WITH DAVA PHARMACEUTICALS
November 8, 2005
IMPAX Laboratories, Inc. (OTC:IPXL) announced today it has entered into a ten
year Exclusive Supply and Distribution agreement with DAVA Pharmaceuticals,
Inc. (DAVA) for IMPAX's 10mg, 20mg, 40mg and 80mg dosage strengths of Oxycodone
Hydrochloride Extended Release Tablets. In exchange for payments of up to $60
million over the next 5 years and sharing of gross profits, DAVA will have exclusive
sales and distribution rights in the United States and Puerto Rico. IMPAX will
be responsible for all manufacturing and regulatory aspects.
Genetic
Engineering News